Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug;90(8):1884-1891.
doi: 10.1111/bcp.16125. Epub 2024 Jun 7.

'Under pressure': The role of therapeutic drug monitoring in the treatment of hypertension

Jorie Versmissen  1   2 , Job van Steenkiste  1   3   4 , Birgit C P Koch  1 , Laura E J Peeters  1   5
Affiliations
Free article
Review

'Under pressure': The role of therapeutic drug monitoring in the treatment of hypertension

Jorie Versmissen et al. Br J Clin Pharmacol. 2024 Aug.
Free article

Abstract

Antihypertensive drugs do not qualify as optimal candidates for therapeutic drug monitoring (TDM), given their obvious physiological effect, the absence of a clear relationship between drug concentrations and pharmacodynamic outcomes and their wide therapeutic range. However, since non-adherence is a major challenge in hypertension management, using drug concentrations can be of value to identify non-adherence as a first step towards better blood pressure control. In this article we discuss the key challenges associated with measuring and interpreting antihypertensive drug concentrations that are important when TDM is used to improve non-adherence. Additionally, we elaborate on the role of TDM in optimizing antihypertensive drug treatment besides addressing non-adherence by highlighting its value in specific patient groups with altered pharmacokinetic parameters such as female vs. male or elderly patients.

Keywords: adherence; antihypertensive drugs; hypertension; therapeutic drug monitoring.

PubMed Disclaimer

References

REFERENCES

    1. Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1‐10. doi:10.3904/kjim.2009.24.1.1
    1. Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol. 2001;52(Suppl 1):5S‐10S. doi:10.1046/j.1365‐2125.2001.0520s1005.x
    1. Rognstad S, Søraas CL, Bergland OU, et al. Establishing serum reference ranges for antihypertensive drugs. Ther Drug Monit. 2021;43(1):116‐125. doi:10.1097/FTD.0000000000000806
    1. Peeters LEJ, Feyz L, Boersma E, et al. Clinical applicability of monitoring antihypertensive drug levels in blood. Hypertension. 2020;76(1):80‐86. doi:10.1161/HYPERTENSIONAHA.120.15038
    1. Mancia G, Kreutz R, Brunström M, et al. ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874‐2071.

Substances

LinkOut - more resources